TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis

Fabio Buttari; Sara Zagaglia; Lorenzo Marciano; Maria Albanese; Doriana Landi; Carolina Gabri Nicoletti; Nicola Biagio Mercuri; Mauro Silvestrini; Leandro Provinciali; Girolama Alessandra Marfia; Francesco Mori; Diego Centonze

doi:10.1016/j.jneuroim.2017.02.007

TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis

Fabio Buttari, Sara Zagaglia, Lorenzo Marciano, Maria Albanese, Doriana Landi, Carolina Gabri Nicoletti, Nicola Biagio Mercuri, Mauro Silvestrini, Leandro Provinciali, Girolama Alessandra Marfia, Francesco Mori, Diego Centonze

Research output: Contribution to journal › Article › peer-review

Abstract

Interferon-beta (IFN-beta) is often discontinued in RRMS patients due to its most common side effect, the flu-like syndrome (FLS). The mechanisms underlying IFN beta-induced FLS symptoms are still unclear. The endocannabinoid system (ECS) is a key regulator of pain and inflammation. Thus we tested the hypothesis that the ECS could be involved in FLS severity by exploring the effect of genetic polymorphisms with functional impact on the ECS, on patient-reported FLS symptoms. GG-carriers of the transient-receptor-potential-vanilloid-1 (TRPV1) single nucleotide polymorphism rs222747 reported greater pain and weakness during FLS. This study suggests that the TRPV1 channel is involved in FLS severity. (C) 2017 Elsevier B.V. All rights reserved.

Original language	Undefined/Unknown
Pages (from-to)	172-174
Number of pages	3
Journal	Journal of Neuroimmunology
Volume	305
DOIs	https://doi.org/10.1016/j.jneuroim.2017.02.007
Publication status	Published - Apr 15 2017

Keywords

Cannabinoid
CB1
Endocannabinoid system
FAAH
Pain
SNP

Access to Document

10.1016/j.jneuroim.2017.02.007

Cite this

Buttari, F., Zagaglia, S., Marciano, L., Albanese, M., Landi, D., Nicoletti, C. G., Mercuri, N. B., Silvestrini, M., Provinciali, L., Marfia, G. A., Mori, F., & Centonze, D. (2017). TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. Journal of Neuroimmunology, 305, 172-174. https://doi.org/10.1016/j.jneuroim.2017.02.007

TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. / Buttari, Fabio; Zagaglia, Sara; Marciano, Lorenzo; Albanese, Maria; Landi, Doriana; Nicoletti, Carolina Gabri; Mercuri, Nicola Biagio; Silvestrini, Mauro; Provinciali, Leandro; Marfia, Girolama Alessandra; Mori, Francesco; Centonze, Diego.

In: Journal of Neuroimmunology, Vol. 305, 15.04.2017, p. 172-174.

Research output: Contribution to journal › Article › peer-review

Buttari, F, Zagaglia, S, Marciano, L, Albanese, M, Landi, D, Nicoletti, CG, Mercuri, NB, Silvestrini, M, Provinciali, L, Marfia, GA, Mori, F & Centonze, D 2017, 'TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis', Journal of Neuroimmunology, vol. 305, pp. 172-174. https://doi.org/10.1016/j.jneuroim.2017.02.007

Buttari, Fabio ; Zagaglia, Sara ; Marciano, Lorenzo ; Albanese, Maria ; Landi, Doriana ; Nicoletti, Carolina Gabri ; Mercuri, Nicola Biagio ; Silvestrini, Mauro ; Provinciali, Leandro ; Marfia, Girolama Alessandra ; Mori, Francesco ; Centonze, Diego. / TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis. In: Journal of Neuroimmunology. 2017 ; Vol. 305. pp. 172-174.

@article{6c44a32f133a4240bc9f25b460107687,

title = "TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis",

abstract = "Interferon-beta (IFN-beta) is often discontinued in RRMS patients due to its most common side effect, the flu-like syndrome (FLS). The mechanisms underlying IFN beta-induced FLS symptoms are still unclear. The endocannabinoid system (ECS) is a key regulator of pain and inflammation. Thus we tested the hypothesis that the ECS could be involved in FLS severity by exploring the effect of genetic polymorphisms with functional impact on the ECS, on patient-reported FLS symptoms. GG-carriers of the transient-receptor-potential-vanilloid-1 (TRPV1) single nucleotide polymorphism rs222747 reported greater pain and weakness during FLS. This study suggests that the TRPV1 channel is involved in FLS severity. (C) 2017 Elsevier B.V. All rights reserved.",

keywords = "Cannabinoid, CB1, Endocannabinoid system, FAAH, Pain, SNP",

author = "Fabio Buttari and Sara Zagaglia and Lorenzo Marciano and Maria Albanese and Doriana Landi and Nicoletti, {Carolina Gabri} and Mercuri, {Nicola Biagio} and Mauro Silvestrini and Leandro Provinciali and Marfia, {Girolama Alessandra} and Francesco Mori and Diego Centonze",

year = "2017",

month = apr,

day = "15",

doi = "10.1016/j.jneuroim.2017.02.007",

language = "Non definita",

volume = "305",

pages = "172--174",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier Science B.V.",

}

TY - JOUR

T1 - TRPV1 polymorphisms and risk of interferon beta-induced flu-like syndrome in patients with relapsing-remitting multiple sclerosis

AU - Buttari, Fabio

AU - Zagaglia, Sara

AU - Marciano, Lorenzo

AU - Albanese, Maria

AU - Landi, Doriana

AU - Nicoletti, Carolina Gabri

AU - Mercuri, Nicola Biagio

AU - Silvestrini, Mauro

AU - Provinciali, Leandro

AU - Marfia, Girolama Alessandra

AU - Mori, Francesco

AU - Centonze, Diego

PY - 2017/4/15

Y1 - 2017/4/15

N2 - Interferon-beta (IFN-beta) is often discontinued in RRMS patients due to its most common side effect, the flu-like syndrome (FLS). The mechanisms underlying IFN beta-induced FLS symptoms are still unclear. The endocannabinoid system (ECS) is a key regulator of pain and inflammation. Thus we tested the hypothesis that the ECS could be involved in FLS severity by exploring the effect of genetic polymorphisms with functional impact on the ECS, on patient-reported FLS symptoms. GG-carriers of the transient-receptor-potential-vanilloid-1 (TRPV1) single nucleotide polymorphism rs222747 reported greater pain and weakness during FLS. This study suggests that the TRPV1 channel is involved in FLS severity. (C) 2017 Elsevier B.V. All rights reserved.

AB - Interferon-beta (IFN-beta) is often discontinued in RRMS patients due to its most common side effect, the flu-like syndrome (FLS). The mechanisms underlying IFN beta-induced FLS symptoms are still unclear. The endocannabinoid system (ECS) is a key regulator of pain and inflammation. Thus we tested the hypothesis that the ECS could be involved in FLS severity by exploring the effect of genetic polymorphisms with functional impact on the ECS, on patient-reported FLS symptoms. GG-carriers of the transient-receptor-potential-vanilloid-1 (TRPV1) single nucleotide polymorphism rs222747 reported greater pain and weakness during FLS. This study suggests that the TRPV1 channel is involved in FLS severity. (C) 2017 Elsevier B.V. All rights reserved.

KW - Cannabinoid

KW - CB1

KW - Endocannabinoid system

KW - FAAH

KW - Pain

KW - SNP

U2 - 10.1016/j.jneuroim.2017.02.007

DO - 10.1016/j.jneuroim.2017.02.007

M3 - Articolo

VL - 305

SP - 172

EP - 174

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -